A-share innovative drug companies have entered the profit realization period, with a series of global academic conferences held from April to June. The Hong Kong innovative drug ETFs GF (513120) and GF (515120) rose over 1% during intraday trading
I'm LongbridgeAI, I can summarize articles.
A-share innovative drug companies are gradually entering a profit realization period, with policy support and market expectations returning to rationality. In the first quarter of 2023, the transaction value of China's innovative drug licensing exceeded USD 60 billion, and 10 new drugs have been approved for market launch. It is expected that multiple global academic conferences will be held from April to June 2026, promoting industry development. Guojin Securities pointed out that the current innovative drug sector is in a "performance realization, valuation repair, and conference catalyst" golden window period
Source: 腾讯新闻 - 财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments